well, I trust Leo(have a friend on this board who knows him personally), and I believe it what was said in the last PR as positive.
hey, we'll see...wathching other plays..and if one pops up, will shift a good portion of CTIX into the other play..hoping soon! then wait for good to great news on CTIX again.
You might check the PR on the in vivo work done on renal cancer...NOT DONE AT KARD. Also...scammers don't generally bet huge amounts of their own money on their scam. I'm just sayin'...there are some strong counter-arguments to your position.
here is a quote: " the Company has received results from in vivo studies conducted at Beth Israel Deaconess Medical Center (“BIDMC”). Cellceutix had earlier reported that they entered into an agreement with BIDMC, a teaching hospital of Harvard Medical School, on an innovative research project with Kevetrin™, the Company’s flagship anti-cancer drug. BIDMC wishes to exploit the nuclear and/or mitochondrial pro-apoptotic function of p53 in melanoma and renal cell carcinoma, two types of cancer that are particularly resistant to therapy.
Research by BIDMC combined Kevetrin™ with sunitinib on cell line 786, a drug-resistant renal cancer. Cellceutix was advised by the researchers that “the Kevetrin/sunitinib combination is the first we’ve used in which actual tumor shrinkage is noted.”